These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38710950)

  • 1. APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease.
    Fortea J; Pegueroles J; Alcolea D; Belbin O; Dols-Icardo O; Vaqué-Alcázar L; Videla L; Gispert JD; Suárez-Calvet M; Johnson SC; Sperling R; Bejanin A; Lleó A; Montal V
    Nat Med; 2024 May; 30(5):1284-1291. PubMed ID: 38710950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do Cardiometabolic Risk Factors Influence Amyloid, Tau, and Neuronal Function in APOE4 Carriers and Non-Carriers in Alzheimer's Disease Trajectory?
    Femminella GD; Taylor-Davies G; Scott J; Edison P;
    J Alzheimers Dis; 2018; 64(3):981-993. PubMed ID: 29966204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.
    Villeneuve S; Vogel JW; Gonneaud J; Pichet Binette A; Rosa-Neto P; Gauthier S; Bateman RJ; Fagan AM; Morris JC; Benzinger TLS; Johnson SC; Breitner JCS; Poirier J;
    JAMA Neurol; 2018 May; 75(5):608-619. PubMed ID: 29482212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment-data from the Dementia Competence Network.
    Benson GS; Bauer C; Hausner L; Couturier S; Lewczuk P; Peters O; Hüll M; Jahn H; Jessen F; Pantel J; Teipel SJ; Wagner M; Schuchhardt J; Wiltfang J; Kornhuber J; Frölich L
    J Neural Transm (Vienna); 2022 Jun; 129(5-6):477-486. PubMed ID: 35061102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
    Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
    Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.
    Abushakra S; Porsteinsson A; Scheltens P; Sadowsky C; Vellas B; Cummings J; Gauthier S; Hey JA; Power A; Wang P; Shen L; Tolar M
    J Prev Alzheimers Dis; 2017; 4(3):149-156. PubMed ID: 29182706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical Localization and Dissociation between Glucose Uptake and Amyloid Deposition in Cognitively Normal APOE*E4 Homozygotic Elders Compared with Patients with Late-Onset Alzheimer's Disease.
    Pardo JV; Lee JT;
    eNeuro; 2018; 5(1):. PubMed ID: 29497704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging and cerebrospinal fluid biomarkers in the search for Alzheimer's disease mechanisms.
    Osorio RS; Pirraglia E; Gumb T; Mantua J; Ayappa I; Williams S; Mosconi L; Glodzik L; de Leon MJ
    Neurodegener Dis; 2014; 13(2-3):163-5. PubMed ID: 24107601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlations between APOE4 allele and regional amyloid and tau burdens in cognitively normal older individuals.
    Hong YJ; Kim CM; Lee JH; Sepulcre J
    Sci Rep; 2022 Aug; 12(1):14307. PubMed ID: 35995824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Integrated Bioinformatics Approach for Identifying Genetic Markers that Predict Cerebrospinal Fluid Biomarker p-tau181/Aβ1-42 Ratio in ApoE4-Negative Mild Cognitive Impairment Patients.
    Sun Y; Bresell A; Rantalainen M; Höglund K; Lebouvier T; Salter H;
    J Alzheimers Dis; 2015; 45(4):1061-76. PubMed ID: 25720397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Thai Nationals, the ApoE4 Allele Affects Multiple Domains of Neuropsychological, Biobehavioral, and Social Functioning Thereby Contributing to Alzheimer's Disorder, while the ApoE3 Allele Protects Against Neuropsychiatric Symptoms and Psychosocial Deficits.
    Tangwongchai S; Supasitthumrong T; Hemrunroj S; Tunvirachaisakul C; Chuchuen P; Houngngam N; Snabboon T; Tawankanjanachot I; Likitchareon Y; Phanthumchindad K; Maes M
    Mol Neurobiol; 2018 Aug; 55(8):6449-6462. PubMed ID: 29307083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitively healthy APOE4/4 carriers show white matter impairment associated with serum NfL and amyloid-PET.
    Tato-Fernández C; Ekblad LL; Pietilä E; Saunavaara V; Helin S; Parkkola R; Zetterberg H; Blennow K; Rinne JO; Snellman A
    Neurobiol Dis; 2024 Mar; 192():106439. PubMed ID: 38365046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline.
    Montagne A; Nation DA; Sagare AP; Barisano G; Sweeney MD; Chakhoyan A; Pachicano M; Joe E; Nelson AR; D'Orazio LM; Buennagel DP; Harrington MG; Benzinger TLS; Fagan AM; Ringman JM; Schneider LS; Morris JC; Reiman EM; Caselli RJ; Chui HC; Tcw J; Chen Y; Pa J; Conti PS; Law M; Toga AW; Zlokovic BV
    Nature; 2020 May; 581(7806):71-76. PubMed ID: 32376954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Thioredoxin-80 is associated with age, ApoE4, and neuropathological biomarkers in Alzheimer's disease: a potential early sign of AD.
    Goikolea J; Gerenu G; Daniilidou M; Mangialasche F; Mecocci P; Ngandu T; Rinne J; Solomon A; Kivipelto M; Cedazo-Minguez A; Sandebring-Matton A; Maioli S
    Alzheimers Res Ther; 2022 Feb; 14(1):37. PubMed ID: 35209952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.
    Weise D; Tiepolt S; Awissus C; Hoffmann KT; Lobsien D; Kaiser T; Barthel H; Sabri O; Gertz HJ
    J Alzheimers Dis; 2015; 48(2):425-32. PubMed ID: 26402006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accumulation of amyloid-β in the brain of mouse models of Alzheimer's disease is modified by altered gene expression in the presence of human apoE isoforms during aging.
    Honda K; Saito Y; Saito H; Toyoda M; Abe R; Saito T; Saido TC; Michikawa M; Taru H; Sobu Y; Hata S; Nakaya T; Suzuki T
    Neurobiol Aging; 2023 Mar; 123():63-74. PubMed ID: 36638682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.